Summit Clinical Research

𝗔𝗹𝗹 𝗽𝗮𝘁𝗵𝗼𝗹𝗼𝗴𝘆 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 𝗮𝗿𝗲 𝗶𝗻. 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴 𝘄𝗶𝗻𝗱𝗼𝘄𝘀 𝗮𝗿𝗲 𝗰𝗹𝗼𝘀𝗲𝗱. 𝗘𝗹𝗶𝗴𝗶𝗯𝗹𝗲 𝟮𝟬𝟮𝟰 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀 𝗵𝗮𝘃𝗲 𝗯𝗲𝗲𝗻 𝗿𝗮𝗻𝗱𝗼𝗺𝗶𝘇𝗲𝗱. As we wrap up March, we’re reflecting on an impactful and complex year at #SummitClinicalResearch. 2024 brought immense challenges, most notably the heartbreaking passing of our co-founder, 𝗗𝗿. 𝗦𝘁𝗲𝗽𝗵𝗲𝗻 𝗔. 𝗛𝗮𝗿𝗿𝗶𝘀𝗼𝗻. His relentless drive continues to guide us, and we are deeply committed to honoring his legacy through the work we do every day. We’re grateful to our families, friends, site staff, and employees for the unwavering support during this time. Despite the sorrow, 2024 was also a pivotal year of 𝗽𝗿𝗼𝗴𝗿𝗲𝘀𝘀 𝗮𝗻𝗱 𝗽𝗿𝗼𝗺𝗶𝘀𝗲: 🔹 The launch of 𝗥𝗲𝘇𝗱𝗶𝗳𝗳𝗿𝗮® (𝗿𝗲𝘀𝗺𝗲𝘁𝗶𝗿𝗼𝗺), the first US FDA-approved MASH drug, was a watershed moment for the field. Summit Clinical Research was proud to play a key role in its development. 🔹 We expect ongoing research into Rezdiffra for label expansion and real-world use, offering new insights into liver and metabolic disease. (See Figure 1)   In 2024, 𝗦𝘂𝗺𝗺𝗶𝘁 𝗶𝗻𝗶𝘁𝗶𝗮𝘁𝗲𝗱 𝟭𝟱 𝗻𝗲𝘄 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝘁𝗿𝗶𝗮𝗹𝘀, bringing our total to 𝟳𝟭 𝘁𝗿𝗶𝗮𝗹𝘀 since our founding in 2018. These trials not only introduce new treatment options—they also drive competition, a common point of discussion with sponsors in the liver and metabolic space. Summit’s deep experience enables us to deliver value across 𝘀𝗶𝘁𝗲 𝘀𝗲𝗹𝗲𝗰𝘁𝗶𝗼𝗻, 𝗲𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁, 𝗽𝗮𝘁𝗶𝗲𝗻𝘁 𝗲𝗻𝗿𝗼𝗹𝗹𝗺𝗲𝗻𝘁, 𝗿𝗲𝘁𝗲𝗻𝘁𝗶𝗼𝗻, 𝗮𝗻𝗱 𝗼𝘃𝗲𝗿𝗮𝗹𝗹 𝘁𝗿𝗶𝗮𝗹 𝘀𝘂𝗰𝗰𝗲𝘀𝘀. Although we saw a 𝟭𝟰% 𝗶𝗻𝗰𝗿𝗲𝗮𝘀𝗲 in new trials year-over-year, the total number fell short of broader industry expectations. Notably, this slowdown appears to reflect 𝗱𝗲𝗹𝗮𝘆𝘀, 𝗻𝗼𝘁 𝗰𝗮𝗻𝗰𝗲𝗹𝗹𝗮𝘁𝗶𝗼𝗻𝘀, and 2025 is already off to a strong start. We’re closely tracking several key contributors to this “stutter step” in 2024: 1. 𝗧𝗵𝗲 𝗹𝗼𝘀𝘀 𝗼𝗳 𝗗𝗿. 𝗛𝗮𝗿𝗿𝗶𝘀𝗼𝗻: His influence accelerated innovation across the entire MASH therapeutic area. From KOL and advisor roles to connecting sponsors and Summit sites, his legacy is embedded in our mission. 2. 𝗥𝗲𝘇𝗱𝗶𝗳𝗳𝗿𝗮’𝘀 𝗹𝗮𝘂𝗻𝗰𝗵: With its approval came necessary shifts in sponsor strategy and increased visibility for the MASH disease space, benefiting the ecosystem overall. 3. 𝗚𝗟𝗣-𝟭 𝗮𝗱𝗼𝗽𝘁𝗶𝗼𝗻: With 1 in 8 US patients using a GLP-1 treatment, developers are adapting trial strategies and endpoints to account for this major variable in metabolic disease management. As we move forward, we remain focused on advancing care, empowering our sites, and supporting our patients. 𝗪𝗵𝗮𝘁 𝗰𝗵𝗮𝗹𝗹𝗲𝗻𝗴𝗲𝘀 𝗼𝗿 𝗼𝗽𝗽𝗼𝗿𝘁𝘂𝗻𝗶𝘁𝗶𝗲𝘀 𝗮𝗿𝗲 𝘆𝗼𝘂 𝘀𝗲𝗲𝗶𝗻𝗴 𝗶𝗻 𝘁𝗵𝗶𝘀 𝗲𝘃𝗼𝗹𝘃𝗶𝗻𝗴 𝗹𝗮𝗻𝗱𝘀𝗰𝗮𝗽𝗲? Let’s connect! Madrigal Pharmaceuticals Naim Alkhouri, MD, FAASLD Mazen Noureddin, MD, MHSc S. Brandon Early

From targeting the right demographics to efficiently managing enrollments with our team of experienced nurses, Summit's #centralrecruitment services are designed to make your clinical trials run smoother and faster. Get in touch with us today to learn how we can help you #accelerateenrollment: centralrecruitment@summitclinicalresearch.com #TrialEnrollment #EfficientRecruitment #ClinicalTrials #SummitClinicalResearch

Millions of people are now living with MASH—Metabolic dysfunction-Associated Steatohepatitis—a progressive liver disease linked to metabolic dysfunction, obesity, and type 2 diabetes. With the first treatment now approved in the US, we are entering a new era of MASH care. Alongside emerging therapies, one message remains clear: Lifestyle modification is—and will continue to be—a core component of MASH management. At the Third Annual Primary Care MASLD/MASH Summit, Prof. Shira Zelber Sagi, a leading expert in liver nutrition, shared practical tools and the latest data to help both clinicians and patients apply lifestyle strategies that complement medical care and improve outcomes. Link to blog: https://lnkd.in/g9DJp8fA Thank you to our sponsors, Novo Nordisk, Boehringer Ingelheim, Pfizer, Siemens Healthineers, Sentrex Health Solutions, Merck, Aegle Medical, Echosens, Eli Lilly and Company and our educational partners, Canadian MASLD Network, Arizona Liver Health, Canadian Association for the Study of the Liver, Canadian Institutes of Health Research | Instituts de recherche en santé du Canada, Pinnacle Clinical Research, Summit Clinical Research, Global Liver Institute, Surfing MASH, The Forum for Collaborative Research, Global NASH Council American Association for the Study of Liver Diseases (AASLD), EASL | The Home of Hepatology, Global NASH Council, European Association for the Study of Obesity (EASO), Aleksander Krag, Sven Francque, Jörn M. Schattenberg, Jonathan G. Stine, MD MSc, FACP, Manal Abdelmalek, European Liver Patients' Association - ELPA, Giada Sebastiani, Sahar Saeed, Naim Alkhouri, MD, FAASLD, Mazen Noureddin, MD, MHSc, Louise Campbell MSc (AP), RMN, RN, FRCP, Madrigal Pharmaceuticals, Perspectum Ltd, Mindray North America, Fibronostics, Sonic Incytes Medical Corp.

🎉 Congratulations to Kat Garcia, Budgets and Contracts Associate, on her 1st #workanniversary at #summitclinicalresearch! 🥳 #teamsummit #clinicalresearch

🎉 Congratulations to Tri Nguyen, Budgets and Contracts Associate, on his 1st #workanniversary at #summitclinicalresearch! 🥳 #teamsummit #clinicalresearch

Recruitment needs fluctuate. Summit’s flexible services adapt to your study demands, handling overflow calls and scaling up or down as studies open or close. Whether you need expert support for geographic-specific outreach or the need for multi-channel marketing solutions to ensure you meet your diversity requirements, we’ve got you covered. Contact us to learn more: centralrecruitment@summitclinicalresearch.com #SummitClinicalResearch #FlexibleSolutions #ClinicalTrials

🎉 Congratulations to Jezel Barrera, Administration Assistant, on her 1st #workanniversary at #summitclinicalresearch! 🥳 #teamsummit #clinicalresearch

SEASON SIX HAS LANDED! S6E1: Two Multispecialty February Conferences and Europe Prepares for Resmetirom SurfingMASH covers two major February conferences: the AASLD Emerging Trends Conference and the Desert Liver Conference, with similar multispecialty perspectives on the entire range of steatotic liver diseases, while Jörn Schattenberg discusses how his practice (and all of Europe) is preparing for resmetirom. https://lnkd.in/eRTPHumS #Steatology #Multispecialty #SteatoticLiverDisease #NASHpodcast #SurfingNASH #FattyLiver

Summit Center of Learning led a Clinical Operations Preceptorship Program for 89bio. Working with support from Pinnacle Clinical Research, this initiative was designed to foster education, innovation, and hands-on learning in clinical trials.   A special thank you to our scientific experts: Dr. Mazen Noureddin, MD, MHSc, Dr. Juan Pablo Arab, Dr. Madhavi Rudraraju, and Dr. Rashmee Patil.   Excited to share how our program is transforming the understanding of therapeutic area knowledge and enhancing the clinical trial journey for participants by prioritizing patient experiences. We’re paving the way for more effective and patient-centered clinical trial in the future!   Calling all clinical operations teams! If you’re interested in attending our program to enhance your skills and knowledge, we’d love to hear from you! Reach out to us for more details. Let’s elevate clinical excellence together. #clinicaltrial #patientengagement